Featured Tests
OmniSeq®
A complete testing portfolio powered by precision medicine.
OmniSeq Comprehensive Assay
OmniSeq Advance Assay
OmniSeq Immune Report Card® Assay
IntelliGEN® Myeloid
NGS assay covering 50 genes associated with myeloid malignancies
PIK3CA Mutation Analysis
FDA approved companion diagnostic for advanced breast cancer
FGFR mutation analysis
FDA approved companion diagnostic for urothelial cancer
News & Announcements
FDA approved, companion diagnostic, QIAGEN therascreen® PIK3CA mutation analysis assay for breast cancer is now available
The assay is intended to aid clinicians in identifying PIK3CA-mutated advanced or metastatic breast cancer patients who may be eligible for treatment with PIQRAY® (alpelisib). [Press Release]
FDA approved, companion diagnostic, QIAGEN therascreen® FGFR mutation analysis assay for locally advanced or metastatic urothelial carcinoma, is now available
The assay is used to assess the eligibility of patients for treatment with the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib), developed by Janssen Biotech, Inc. (Janssen). [Press Release]
PD-L1 (SP142) IHC in TNBC
Integrated Oncology now expands the offering of the VENTANA PD-L1 (SP142) IHC assay for use in metastatic triple-negative breast cancer (TNBC) tumor samples. This companion diagnostic assay may help physicians determine which TNBC patients may benefit most with TECENTRIQ® (atezolizumab) plus chemotherapy. Learn more
NTRK Gene Fusions
TRK fusion proteins are oncogenic drivers that occur in a broad range of tumors across adult and pediatric cancers. Genomic profiling using either the OmniSeq AdvanceSM assay or the OmniSeq Comprehensive® assay can identify actionable NTRK gene fusions for TRK inhibitor treatment selection.